Drug Profile
SPI 040
Latest Information Update: 07 Apr 2003
Price :
$50
*
At a glance
- Originator ALZA Corporation
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 07 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 28 Jun 2001 ALZA Corporation has been acquired by Johnson & Johnson
- 23 Apr 1999 Sequus has been merged into ALZA Corporation